EGFR and non-small cell lung carcinoma: In a large phase III trial that enrolled 1125 patients with advanced NSCLC (FLEX) (30), cetuximab was shown to improve overall survival (11.3 vs. 10.1 months, p = 0.004) when combined with cisplatin and vinorelbine, with greater efficacy noted in patients with higher EGFR protein expression (31).